Exothera will use the NevoLine platform for the manufacturing of viral vector-based gene therapies and viral vaccines. The technology works through intensification and chaining of unit steps into a continuous process, which allows users to achieve high yields. The platform increases volumetric production, offering significant development and production cost reductions.

The NevoLine Upstream platform. Image courtesy of Univercells Technologies.

The platform is an integrated and automated solution for cost-effective production of viral vaccines, viral vectors, and oncolytic viruses. The equipment will be installed within its 9,690-sq-ft good manufacturing practice (GMP) facility based in Jumet, Belgium. The site will have dedicated upstream and downstream process development production areas, as well as clinical and commercial GMP manufacturing capabilities. At the same site, a second 59, 200-sq-ft GMP facility will open in January 2022.